td cowen - Search News

TD Cowen initiates Crinetics stock with Buy rating, sees high potential

TD Cowen began coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating, citing the company's strong position in the endocrine market and the high potential of its product pipeline. The firm's analyst highlighted Crinetics' leading role in the field and the promising outlook for its treatments.

Business Insider · 17h

Crinetics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Crinetics (CRNX) with a Buy rating and no price target The firm says Crinetics is “revered” in the endocrine

Hosted on MSN · 1d

Cowen initiates Repligen stock with Buy rating, $200 target

TD Cowen began coverage on Repligen Corporation (NASDAQ:RGEN), a prominent bioprocessing company, with a Buy rating and a price target set at $200. The firm highlighted Repligen's strong position for potential industry-leading growth and margin expansion,

Investing.com on MSN · 12h

TD Cowen raises McDonald's stock target to $305, keeps Hold rating

TD Cowen adjusted its outlook on McDonald's Corporation (NYSE:MCD) shares, raising the price target from $300.00 to $305.00. The firm maintained its Hold rating on the fast-food giant's stock, which is currently trading near its 52-week high at $308.

Business Insider · 1d

Repligen initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Repligen (RGEN) with a Buy rating and $200 price target Repligen is well positioned for “industry-leading”

16h

TD Cowen Sticks to Its Buy Rating for Axis Capital (AXS)

In a report released today, Andrew Kligerman from TD Cowen maintained a Buy rating on Axis Capital (AXS – Research Report), with a price target ...

1don MSN

Merck (MRK) Downgraded by TD Cowen Over Keytruda, Gardasil Concerns

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

The Manila Times14h

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

TD Cowen Reaffirms Their Buy Rating on Amicus (FOLD)

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report), with a price target of $20.00.

1don MSN

Why GDS Holdings Stock Zoomed Higher Today

News of a significant price-target boost from an analyst tracking GDS Holdings ( GDS 7.20%) was the main catalyst behind the ...

BioSpace4d

After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Why GDS Holdings (GDS) Is Climbing Today

China-based GDS Holdings (GDS) is surging 6% after investment bank TD Cowen raised its price target on the shares. The ...

Palvella Therapeutics (NASDAQ:PVLA) Now Covered by TD Cowen

TD Cowen began coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Free Report) in a research report released on Wednesday morning, MarketBeat.com reports. The firm issued a buy rating and a ...

TMCnet6h

Teledyne to Participate at the TD Cowen Aerospace & Defense Conference

Teledyne Technologies Incorporated (NYSE:TDY) today announced that George Bobb, President and Chief Operating Officer, and Jason VanWees, Vice Chairman, will present at the TD Cowen 46th Annual ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics